Friday, August 20, 2021 4:12:06 PM
3 Reasons $RGBP Could Be Sold For CASH$$
1) The Company is Down, But Not Out.
2) The Science is MRNA Blockbuster But Bank Account isn’t.
3) Dr Koos is near the End of a long Career.
Thanks to OTCShotcaller Here's Reason #4
#4- It's going to take hundreds of millions of dollars to put the re-activated Patents into FDA Approved Clinical Trials.
Here's a link that provides an estimate for this.
https://www.jhsph.edu/news/news-releases/2018/cost-of-clinical-trials-for-new-drug-FDA-approval-are-fraction-of-total-tab.html
The average or "median" cost in 2015-2016 was $16 Million per clinical trial. Today it would be much higher.
Also, this article points out that for clinical trials that involve examining "a drug's ability to prevent a clinically meaningful outcome..", the median cost is much higher, i.e. $65 Million per trial, and again that was back in 2015-2016.
So yes as I said, to put those re-activated Patents into clinical trials is going to cost a absolute FORTUNE....ALL CASH!!
Big Pharma Buy Out is the only thing that makes sense, IMO.
Opinion Only..
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM